Brain-boosting substances are all the rage

Brain-boosting substances are all the rage



Brain-boosting substances are all the rage

A FILM FROM 2011 entitled “Limitless” is often credited with driving an uptick in interest in products that improve focus or enhance memory. It depicts a struggling writer whose life is transformed by a smart pill. More recently the real-life version of nootropic supplements, as such boosters are called, have received celebrity endorsements. Bella Hadid, a supermodel, is behind Kin Euphorics, a brand which offers consumers the chance to “achieve an elevated state of health, mood or well-being”. Joe Rogan, the alpha-male host of the world’s most popular podcast, endorses “Alpha Brain”, which, he says, “seems to fire up” that organ.

Alpha Brain is made by Onnit, a supplements firm co-founded by Mr Rogan in 2010 to “inspire a journey towards total human optimisation”. The brand caught the eye of Unilever, a soup-to-soap conglomerate, which bought it for an undisclosed sum in 2021. Its consumer-goods rivals have piled in. Reckitt Benckiser, the parent company of brands such as Durex and Strepsils, sells Neuriva. They are competing with—and eyeing up—a slew of supplements startups. Polaris, a research firm, reckons global sales of nootropics, which hit $11bn in 2021, will grow at an average annual rate of almost 15% until 2030.

Nootropics are usually an alphabet soup of ingredients: amino acids such as L-theanine, herbal extracts such as ashwagandha, probiotics, vitamins and a bewildering variety of mushrooms. Neuriva contains branded forms of coffee-fruit extract and phosphatidylserine, a type of fat. The ingredients are being combined to form novel products that claim to offer various brain-stimulating benefits. Their emergence has coincided with a post-pandemic interest in wellness. They appeal both to older consumers concerned about cognitive decline, and to younger ones keen to excel in the face of millennial angst (and to imitate Mr Rogan and Ms Hadid).

2024-03-07 09:18:12
Post from www.economist.com

Exit mobile version